We are live on ! Find out more
BAMS

Bellevue Asset Management (Switzerland) Portfolio holdings

AUM $656M
1-Year Est. Return 11.45%
This Fund
S&P 500
This Quarter Est. Return
+4.85%
1 Year Est. Return
+11.45%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$721M
AUM Growth
+$3.8M
Cap. Flow
-$22.4M
Cap. Flow %
-3.1%
Top 10 Hldgs %
29.13%
Holding
154
New
13
Increased
38
Reduced
45
Closed
15

Top Buys

Rank Stock Value
1
ENDP
Endo International plc
ENDP
+$6.22M
2
COR icon
Cencora
COR
+$5.63M
3
ILMN icon
Illumina
ILMN
+$5.46M
4
REGN icon
Regeneron Pharmaceuticals
REGN
+$4.98M
5
PRGO icon
Perrigo
PRGO
+$4.77M

Top Sells

Rank Stock Value
1
CTRX
CATAMARAN CORP COM STK (CDA)
CTRX
+$18.9M
2
BAX icon
Baxter International
BAX
+$9.56M
3
CNC icon
Centene
CNC
+$8.47M
4
LCI
Lannett Company, Inc.
LCI
+$6.61M
5
MOH icon
Molina Healthcare
MOH
+$6.39M

Sector Composition

Rank Sector Weight
1 Healthcare 90.06%
2 Financials 0.8%
3 Industrials 0.48%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BIIB icon
1
Biogen
BIIB
$30.5B
$29.4M 4.08%
72,760
+2,030
+3% +$815K
GILD icon
2
Gilead Sciences
GILD
$164B
$27.5M 3.82%
234,900
+1,090
+0.5% +$119K
CELG
3
DELISTED
Celgene Corp
CELG
$26.5M 3.67%
228,680
+2,890
+1% +$330K
ABT icon
4
Abbott
ABT
$183B
$22.7M 3.15%
463,000
-44,000
-9% -$2.11M
MDT icon
5
Medtronic
MDT
$110B
$20.7M 2.88%
280,000
-60,000
-18% -$4.58M
REGN icon
6
Regeneron Pharmaceuticals
REGN
$79.1B
$19.8M 2.75%
38,800
+10,205
+36% +$4.98M
ILMN icon
7
Illumina
ILMN
$30.2B
$18.1M 2.51%
85,056
+27,941
+49% +$5.46M
VTRS icon
8
Viatris
VTRS
$20.6B
$15.3M 2.12%
225,000
+60,000
+36% +$4.24M
AGN
9
DELISTED
Allergan plc
AGN
$15M 2.08%
49,420
+690
+1% +$206K
ENDP
10
DELISTED
Endo International plc
ENDP
$15M 2.08%
188,000
+72,000
+62% +$6.22M
AMGN icon
11
Amgen
AMGN
$220B
$14.9M 2.06%
96,866
-13,000
-12% -$2.08M
ESRX
12
DELISTED
Express Scripts Holding Company
ESRX
$14.2M 1.97%
160,000
+20,000
+14% +$1.75M
UNH icon
13
UnitedHealth
UNH
$375B
$14M 1.95%
115,000
– –
SYK icon
14
Stryker
SYK
$129B
$13.4M 1.87%
140,700
-5,000
-3% -$474K
BDX icon
15
Becton Dickinson
BDX
$47B
$12.8M 1.78%
92,896
+32,823
+55% +$4.53M
STJ
16
DELISTED
St Jude Medical
STJ
$11M 1.52%
150,000
-1,000
-0.7% -$72.2K
VRTX icon
17
Vertex Pharmaceuticals
VRTX
$123B
$10.9M 1.52%
88,500
-5,000
-5% -$630K
CYTO
18
DELISTED
Altamira Therapeutics Ltd
CYTO
$10.7M 1.49%
27
– –
KITE
19
DELISTED
Kite Pharma, Inc.
KITE
$10.7M 1.48%
175,000
+7,000
+4% +$399K
ZBH icon
20
Zimmer Biomet
ZBH
$19B
$10.4M 1.45%
98,365
– –
CAH icon
21
Cardinal Health
CAH
$56B
$10.3M 1.43%
123,000
+33,000
+37% +$2.91M
TEVA icon
22
Teva Pharmaceuticals
TEVA
$40.5B
$9.87M 1.37%
166,950
+26,950
+19% +$1.66M
JAZZ icon
23
Jazz Pharmaceuticals
JAZZ
$16.4B
$9.86M 1.37%
56,000
-2,500
-4% -$449K
ALXN
24
DELISTED
Alexion Pharmaceuticals
ALXN
$9.35M 1.3%
51,746
-21,000
-29% -$3.62M
CYH icon
25
Community Health Systems
CYH
$416M
$9.34M 1.3%
179,383
+94,683
+112% +$4.25M
1
2 3 4 5

Similar funds

VFAM
Valley Forge Asset Management King Of Prussia, Pennsylvania $645M AUM 5.8% 1-Year Est. Return
MSU
Maple Securities USA Jersey City, New Jersey $672M AUM 1.03% 1-Year Est. Return
PSI
Pinnacle Summer Investments Fairfax, Virginia $678M AUM 9.54% 1-Year Est. Return
SFP
Santa Fe Partners Santa Fe, New Mexico $608M AUM 8.76% 1-Year Est. Return
MCM
Mazama Capital Management Portland, Oregon $544M AUM 9.52% 1-Year Est. Return
NMIS
Northwestern Mutual Investment Services Milwaukee, Wisconsin $525M AUM 2.45% 1-Year Est. Return
SM
Stratton Management King Of Prussia, Pennsylvania $824M AUM 1.55% 1-Year Est. Return
ZAM
Zenit Asset Management Stockholm, Sweden $450M AUM 8.32% 1-Year Est. Return

Bellevue Asset Management (Switzerland)'s Q2 2015 Portfolio in Review

As of Q2 2015, Bellevue Asset Management (Switzerland) held 154 positions worth $721M, up 0.53% from $717M the previous quarter. Its ten largest holdings account for 29% of the portfolio.

Bellevue Asset Management (Switzerland) withdrew a net $22.4M in Q2 2015, closing 15 positions and reducing 45 holdings. Its most notable exit was CATAMARAN CORP COM STK (CDA), an estimated $18.9M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 90% of assets, up from 85% a quarter earlier, followed by Financials and Industrials.

Against the trend, Bellevue Asset Management (Switzerland) opened a new position in Horizon Therapeutics Public Limited Company Ordinary Shares worth $5.21M.

  • Bellevue Asset Management (Switzerland)'s largest Q2 2015 buy was Horizon Therapeutics Public Limited Company Ordinary Shares: 150,000 shares worth $5.21M.
  • Bellevue Asset Management (Switzerland) added most to Endo International plc in Q2 2015, an estimated $6.22M increase.
  • Bellevue Asset Management (Switzerland)'s biggest Q2 2015 reduction was Centene, cutting an estimated $8.47M.
  • Bellevue Asset Management (Switzerland) fully exited CATAMARAN CORP COM STK (CDA) in Q2 2015, selling an estimated $18.9M.
  • Bellevue Asset Management (Switzerland)'s ten largest holdings make up 29% of its $721M portfolio in Q2 2015.
  • Bellevue Asset Management (Switzerland) opened 13 new positions and closed 15 in Q2 2015.
  • Bellevue Asset Management (Switzerland)'s portfolio value rose 0.53% quarter-over-quarter to $721M.

Based on Bellevue Asset Management (Switzerland)'s 13F filing for Q2 2015, filed 12 Aug 2015.